PROPANE STUDY

PROBING THE ROLE OF SODIUM CHANNELS IN PAINFUL NEUROPATHIES

Coordinatore	FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA    more  Organization address address: VIA CELORIA 11 city: MILANO postcode: 20133 contact info Titolo: Dr. Nome: Francesca Cognome: Grechi Email: send email Telefono: +39 0223942320
Nazionalità Coordinatore	Italy [IT]
Totale costo	6˙398˙298 €
EC contributo	4˙845˙089 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2016-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA  Organization address address: VIA CELORIA 11 city: MILANO postcode: 20133 contact info Titolo: Dr. Nome: Francesca Cognome: Grechi Email: send email Telefono: +39 0223942320	IT (MILANO)	coordinator	709˙286.00
2	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Ms. Nome: Laurent Cognome: Louwies Email: send email Telefono: +31 433884107	NL (MAASTRICHT)	participant	1˙183˙453.00
3	YALE UNIVERSITY  Organization address address: WHITNEY AVENUE 155 ROOM 214 city: NEW HAVEN postcode: 06520 8337 contact info Titolo: Mr. Nome: Jeffrey Cognome: Mcguinness Email: send email Telefono: +001 2037855536	US (NEW HAVEN)	participant	824˙676.00
4	Fondazione Centro San Raffaele  Organization address address: Via Olgettina 60 city: Milano postcode: 20132 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Pedrazzi Email: send email Telefono: +39 0226435480 Fax: +39 0226434717	IT (Milano)	participant	536˙806.00
5	CONVERGENCE PHARMACEUTICALS LIMITED  Organization address address: HIGH HOLBORN 90 city: LONDON postcode: WC1 6XX contact info Titolo: Mr. Nome: Simon Cognome: Tate Email: send email Telefono: +44 1223755501 Fax: +44 1223497114	UK (LONDON)	participant	450˙023.00
6	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Claire Cognome: Faichnie Email: send email Telefono: 441613000000	UK (MANCHESTER)	participant	416˙069.00
7	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  Organization address address: Rue Michel -Ange 3 city: PARIS postcode: 75794 contact info Titolo: Ms. Nome: Sophie Cognome: Deschaintres Email: send email Telefono: +33 493954260 Fax: +33 4 92960339	FR (PARIS)	participant	340˙672.00
8	DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT EV  Organization address address: AUF M HENNEKAMP 65 city: DUESSELDORF postcode: 40225 contact info Titolo: Prof. Nome: Dan Cognome: Ziegler Email: send email Telefono: +49 21133820 Fax: +49 2113382244	DE (DUESSELDORF)	participant	308˙407.00
9	CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL  Organization address address: Via Giuseppe Mussi 1 city: MILANO postcode: 20154 contact info Titolo: Mrs. Nome: Carla Cognome: Finocchiaro Email: send email Telefono: +39 023108331 Fax: +39 0233614064	IT (MILANO)	participant	75˙697.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Neuropathic pain is a frequent feature of peripheral neuropathy adversely impacting patients’ quality of life and increasing health care costs. Not all individuals with neuropathy develop pain and it is not possible to predict who is more or less susceptible among those with similar risk exposure. Inability to identify high-risk individuals and drug-responder patients and lack of drugs acting on target sites for which there is strong evidence of pathogenicity explain the disappointing effect of current treatments. The PROPANE STUDY aims to address these issues through a solid clinical and genetic approach employing an innovative technological platform. The main objectives are to resolve the genetic architecture of painful neuropathy achieving a stratification of high-risk neuropathic pain patients by novel biomarkers, to deepen understanding of underlying mechanisms and druggable targets and to identify new molecules tailored to potentially drug-responder patients and determine their effects in pre-clinical settings. Results will advance the field beyond the current state-of-the-art opening a window upon a validated individualized pain medicine and having an innovative impact both on patients’ care and market applications. These aims will be achieved by a complementary approach based on targeted sequencing of the 5 sodium channel genes expressed in the nociceptive pathway and identification of new targets by unbiased whole exome sequencing and transcriptome assay. Melding of these two approaches offers a close-to-optimal balance between highly-focused, challenging but clearly achievable goals (sodium channels in pain) and a broader unbiased approach that will capture and deliver other targets and approaches from our unique patient population. Our strong preliminary findings were the departure point of the PROPANE STUDY and the expected results could be translated into solutions able to benefit a large population of pain patients in terms of diagnosis and treatment.'